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Preamble
This document is an American College of Cardiology
Foundation (ACCF) health policy statement and is in-
tended to promote or advocate a position, be informational
in nature, and offer guidance to the stakeholder community
regarding the ACCF’s stance on healthcare policies and
programs. Health policy statements are not intended to offer
clinical guidance and do not contradict existing ACCF
clinical policy. They are overseen by the ACCF Clinical
Quality Committee (CQC), the group responsible for
developing and implementing all health policy statement
policies and procedures related to topic selection, commis-
sioning writing committees, and defining document devel-
opment methodologies. The CQC brings together various
areas of the College such as the Advocacy Committee, the
National Cardiovascular Data Registry, the ACCF/AHA
(American Heart Association) Task Forces on Guidelines
and Performance Measurement, and the ACCF Appropriate
Use Criteria Steering Committee. The CQC recommended
the development of this health policy statement to update the
ACCF’s official position on therapeutic substitution.
To avoid actual, potential, or perceived conflicts of
interest that may arise as a result of industry relationships or
personal interests among the writing committee, all mem-
bers of the writing committee, as well as peer reviewers of
the document, are asked to disclose all current healthcare-
related relationships, including those existing 12 months
before initiation of the writing effort. The CQC reviews
these disclosures to determine what companies make prod-
ucts (on market or in development) that pertain to the
document under development. Based on this information, a
writing committee is formed to include a majority of
members with no relevant relationships with industry and
other entities (RWI), led by a chair with no relevant RWI.Authors with relevant RWI are not permitted to draft or
vote on text or recommendations pertaining to their RWI.
RWI is reviewed on all conference calls and updated as
changes occur. Author and peer reviewer RWI pertinent to
this document are disclosed in Appendixes 1 and 2, respec-
tively. In addition, to ensure complete transparency, authors’
comprehensive disclosure information—including RWI not
pertinent to this document—is available as an online sup-
plement to this document. Disclosure information for the
ACCF CQC is also available online at www.cardiosource
.org/ACC/About-ACC/Leadership/Guidelines-and-
Documents-Task-Forces.aspx, as well as the ACCF disclo-
sure policy for document development at www.cardiosource.org/
Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/Relationships-With-Industry-Policy.aspx.
The work of the writing committee was supported
exclusively by the ACCF without commercial support.
Writing committee members volunteered their time to this
effort. Conference calls of the writing committee were
confidential and attended only by committee members.
Joseph P. Drozda, Jr., MD, FACC
Chair, ACCF Clinical Quality Committee
1. Introduction
1.1. Purpose of This Document
Therapeutic interchange/substitution has been defined as the
dispensation of drugs alternative to those that have been
specifically prescribed. These alternative drugs may be either
generic drugs or drugs that are similar, albeit not identical.
These drugs may also be chemically different with different
pharmacokinetic properties but which are believed to be
therapeutically similar.
The concepts of therapeutic interchange and substitution
have received increasing attention. One of the most com-
mon reasons is the development of multiple drugs in a
similar class, for example, angiotensin-converting enzyme
(ACE) inhibitors, beta-blockers, diuretics, statins, or cal-
cium channel blockers. A second group of common reasons
is the development of slightly differing drugs within the
same class. Perhaps the most important driving issues are
economic. As healthcare costs rise inexorably and the limits
of patent protections are either exceeded, circumvented, or
ignored worldwide, generic drugs and devices are often
developed and marketed under the understanding that they
provide the same benefit and safety but with greatly reduced
costs. These issues are all central to the concepts of
therapeutic interchange and substitution and are the focus
of this health policy statement.
This document is meant to stimulate discussion of the
following issues and highlight the controversies that sur-
round this increasingly widely used strategy of care that can
have far-reaching implications.
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2. Do state, national, and international regulatory agencies
control the process?
3. Can therapeutic interchange/substitution occur without
physician knowledge?
4. Is there a difference between drugs and biologics in terms
of therapeutic interchange/substitution?
5. Are generics really equivalent?
6. Does the burgeoning field of pharmacogenomics affect
therapeutic interchange/substitution?
7. Are there specific patient groups who are at increased
risk with therapeutic interchange/substitution?
8. How do we address the conflict between evidence-based
data and economic pressures?
9. How does the ACCF/AHA guideline process address
the issue of drug class versus specific agent?
1.2. Document Development Process
The writing committee included ACCF and AHA mem-
bers representing general cardiology, geriatric cardiology,
pediatric cardiology, neurology, critical care, and clinical
pharmacology who met the College’s disclosure require-
ments as described in the Preamble. The committee con-
vened its work by conference call and e-mail to finalize the
document outline, develop the initial draft, revise the draft
based on committee feedback, and ultimately sign off on the
document for external peer review. Peer review consisted of
Table 1. Key Terms and Definitions Related to Therapeutic Inte
Term
ioavailability The rate and extent to which a drug’s act
site of action.
ioequivalence The absence of a significant difference in
same molar dose under similar conditi
iologics Biological agents that are derived from li
may have either a therapeutic or diagn
iosimilars “Generic” biologics that are copies of a th
through an abbreviated process.
ritical dose drugs Drugs in which comparatively small diffe
serious drug reactions.
eneric substitution The act of switching between a branded
arrow therapeutic index drugs Drugs identified as having less than a 2-f
than a 2-fold difference between the m
and effective use of the drug requires c
range Book (i.e., Approved
Drug Products with Therapeutic
Equivalence Evaluations)
An FDA publication that identifies drug pr
to whether generic versions of medicat
innovator company (1).
Pharmaceutical equivalents Drug products that contain the identical a
administration, as well as meet compe
Reference innovator The initially FDA-approved drug in this ca
Therapeutic equivalent Drug products that are approved as safe
manufactured in compliance with curre
Therapeutic interchange The act of dispensing, with the authorizat
similar but may be chemically differen
is based on the premise that the subst
safety profile.
Therapeutic substitution The act of therapeutic interchange that oFDA indicates U.S. Food and Drug Administration.13 reviewers representing 173 comments. Comments were
reviewed and addressed by the writing committee. A CQC
liaison served as lead reviewer to ensure that all comments
were addressed adequately. Both the writing committee and
CQC approved the final document to be sent for board
review. The AHA Science Advisory and Coordinating
Committee and the ACCF Board of Trustees reviewed the
document, including all peer review comments and writing
committee responses, and approved the document in May
and June 2011, respectively. The document is considered
current until the CQC revises it or withdraws it from
publication.
1.3. Definitions, Terminology, and Regulations
When approaching the clinical and legal complexity sur-
rounding generic substitution and therapeutic interchange,
healthcare providers must be well versed in the terminology
used by the U.S. Food and Drug Administration (FDA),
the generics approval process, and the current regulatory
issues surrounding bioequivalence. See Table 1 for the key
terms and definitions used in this document.
1.3.1. Terminology
All prescription and over-the-counter generic medications
must meet the standards established by the FDA, which
were initially proposed under the Drug Price Competition
and Patent Term Restoration Act of 1984 (“Hatch-
nge/Substitution
Definition
redient is absorbed from the drug product and becomes available at its
ailability between a drug product and its innovator when administered at the
an appropriately designed study.
urces such as cultures of bacteria, viruses, or human or animal tissue and
intent.
utic protein, not manufactured by an innovator company, and approved
in dose or concentration may lead to serious therapeutic failures and/or
nd its therapeutically equivalent generic version.
ference between the median lethal and the median effective dose, having less
m toxic and minimum effective concentrations in the blood, and where safe
l titration and patient monitoring.
s approved on the basis of safety and effectiveness. It contains information as
re considered to be therapeutic equivalents to the drugs manufactured by the
ts of the same active ingredient in the same dosage form and route of
r other applicable standards of strength, quality, purity, and identity.
.
fficacious; are pharmaceutical equivalents; are bioequivalent; and are
od Manufacturing Practice regulations.
the initial prescriber, an alternative drug that is believed to be therapeutically
different category, with different pharmacokinetic properties. This interchange
drug will provide a similar clinical efficacy, desired outcome, and
without the prior authorization of the initial prescriber.rcha
ive ing
bioav
ons in
ving so
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erape
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new generic product, it concludes and ratifies that the
generic is therapeutically equivalent to its corresponding
reference innovator product. The generic product can
therefore be substituted at the time of dispensing for the
reference innovator or brand-name product on the expec-
tation that the generic will produce the identical clinical
response with a similar safety profile. The FDA classifies
products as therapeutically equivalent when they are
approved as safe and efficacious, are pharmaceutical
equivalents, are bioequivalent, and are manufactured in
compliance with current Good Manufacturing Practice
regulations (1).
Drug products are considered pharmaceutical equivalents
if they contain the identical amounts of the same active
ingredient in the same dosage form and route of adminis-
tration, as well as meet compendia or other applicable
standards of strength, quality, purity, and identity. How-
ever, generic medications may differ from the innovator
product in shape, drug release mechanisms, scoring config-
urations, and shelf lives/expiration times (1). Standards of
pharmaceutical equivalence do not require that additives
such as fillers, coatings, flavoring, coloring, and binders
utilized in generic formulations be similar or identical to the
innovator counterparts. It is important to note that some
additives traditionally thought to be inert, such as alcohol
sugars, cyclodextrans, and polysorbate-80, may alter a drug’s
dissolution, thereby impacting its bioavailability (3–5).
The FDA defines bioequivalence as the absence of a
ignificant difference in the rate and extent to which the
ctive ingredient or active moiety in pharmaceutical equiv-
lents or pharmaceutical alternatives become available at the
ite of drug action (or bioavailability) when administered at
he same molar dose under similar conditions in an appro-
riately designed study (1). In other words, if the innovator
nd generic drugs are bioequivalent, then they should
xhibit equivalent drug concentration-time profiles in the
lood (6).Figure 1. Diagram Illustrating Possible Bioequivalence Study Outcomes.3.2. Generics
hen submitting an Abbreviated New Drug Application
or a generic drug, a manufacturer must submit 1 bio-
quivalence studies in which subjects are administered the
eneric and innovator products, and drug blood concentra-
ions are measured to determine the maximum drug con-
entration (Cmax) and total drug exposure (area under the
urve [AUC]) (7,8). These studies typically consist of 12 to
6 healthy male and female volunteers using the highest
trength of a drug’s product line and can be either single-
ose crossover or multidose steady-state studies. When
valuating bioequivalence parameter results, 2 one-sided
ioequivalence tests may be performed (6,9). One test
erifies that the bioavailability of the generic is not 20%
ess than that of the innovator product, whereas the other
onfirms the bioavailability of the innovator product is not
20% less than the generic product (6,9). The use of this
20% rule” is based on a decision by FDA medical experts
ho suggest that for most drugs, a 20% difference in the
ctive ingredients’ blood concentrations is not clinically
ignificant (1). For the 2 products to be deemed bioequiva-
ent, the 90% confidence interval of the geometric mean of
he ratio of the generic compared with the innovator
roduct of the Cmax and AUC values must lie between 80%
nd 125% (6,8) (see Figure 1).
Therefore, the established bioequivalence limits are 80%
o 125%. Once approved, a generic product is assigned a
herapeutic rating and is listed in the FDA’s Approved Drug
roducts with Therapeutic Equivalence Evaluation, also re-
erred to as the Orange Book (1). Therapeutically equivalent
rugs are assigned either an A rating or AB rating. Table 2
ummarizes the FDA coding system for therapeutic equiv-
lence for drug products.
.3.3. Bioequivalence
ver the past decade, many issues have arisen that have tested
he FDA’s current bioequivalence criteria, particularly as they
elate to narrow therapeutic index and critical dose drugs as
1291JACC Vol. 58, No. 12, 2011 Holmes et al.
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in the field of heart failure relating to the fixed-dose combi-
nation of hydralazine/isosorbide dinitrate (as studied in
A-HeFT [African-American Heart Failure Trial]) versus ge-
neric hydralazine and generic nitrates. This has great implica-
tions because of the lack of bioequivalence between the different
formulations of isosorbide dinitrate and hydralazine (10).
The issue of bioequivalence also has significant clinical
impact specifically related to narrow therapeutic index drugs.
These drugs are identified as those having less than a 2-fold
difference between the median lethal and the median effective
dose, having less than a 2-fold difference between the mini-
mum toxic and minimum effective concentrations in the blood,
and where safe and effective use of the drug requires careful
titration and patient monitoring (11). The critical dose drugs
are those drugs in which comparatively small differences in
dose or concentration may lead to serious therapeutic failures
and/or serious drug reactions (11). The impact of this impre-
cision in defining the parameters of a narrow therapeutic index
and critical dosing medication schedules is important but
difficult to measure. The FDA does not formally designate
specific critical dose and narrow therapeutic index drug clari-
fications; however, possible examples would include certain
antiepileptics, antiarrhythmics, thyroid preparations, immuno-
suppressants, and anticoagulants (Table 3). Additionally, many
healthcare providers, scientists, and regulatory agencies have
expressed alarm that bioequivalent generic and brand-name
critical dose and narrow therapeutic index drugs may not be
equivalent in their effects on various clinical parameters. Con-
cern also exists regarding the potential for generic-to-generic
switches with these drugs as bioequivalence assessments re-
quired by the FDA compare each generic to its innovator
product. Generics are not compared with each other. Finally,
bioequivalence studies are not always published in the literature
Table 2. FDA Coding System for Therapeutic Equivalence for D
Code
A Drug products that the FDA considers to be therapeutically equivalent
● There are no known or suspected bioequivalence problems. These ar
aerosolization), AO (injectable oil solutions), AP (injectable aqueous
● Actual or potential bioequivalence problems have been resolved with
designated AB.* Drugs coded as AB under a specific product headin
under that heading.
B Drug products that the FDA at this time considers not to be therapeut
following is true:
● Actual or potential bioequivalence problems have not been resolved
forms rather than the active ingredients.
● The quality standards are inadequate, or the FDA has had an insuffic
● The drug products are currently under regulatory review.
The subcodes consist of BC (extended-release capsules, injectables, ta
problems); BE (delayed release oral dosage forms); BN (aerosol-nebuli
bioequivalence problems); BR (suppositories and enemas); BS (produc
insufficient data); or B†.
*A number is added to the end of the code (e.g., AB1, AB2), which indicates that 1 referen
medications are identified only when there are at least 2 potential reference drug products that a
an A or B code before new information raising significant questions about therapeutic equivalen
FDA completes its investigation and review.
FDA indicates U.S. Food and Drug Administration.
Table content adapted from U.S. Food and Drug Administration (1).and may be difficult to obtain.In April 2010, the FDA Advisory Committee for Phar-
maceutical Science and Clinical Pharmacology evaluated
these concerns and recommended that critical dose/narrow
therapeutic index drugs are a distinct group of products; the
FDA should develop a list of critical dose/narrow therapeu-
tic index drugs; and the current bioequivalence standards are
not sufficient for these drugs (12).
Additional evaluation of bioequivalence may involve
measurement of pharmacodynamic effects. These may in-
clude, for example, measuring platelet aggregation. The
linkage between pharmacodynamic effects and clinical out-
comes remains uncertain (13). It must also be remembered
that current methods of determining bioequivalence and
therapeutic equivalence do not account for pharmacokinetic
variation. Better knowledge of pharmacokinetic variation
has significant consequences for current federal regulations
and state laws regulating therapeutic substitution.
1.3.4. Biologics and Biosimilars
As patents for several biologic products manufactured using
recombinant DNA technology are nearing expiration, the issue
of “generic” biologic interchange will need to be addressed
roducts
cription
er pharmaceutically equivalent products, that is, drugs for which:
ignated AA (conventional dosage forms), AN (solutions and powders for
ns), or AT (topical products)
uate in vitro and/or in vivo evidence supporting bioequivalence. These are
onsidered to be therapeutically equivalent only to other drugs coded as AB
quivalent to the other pharmaceutically equivalent products for which 1 of the
equate evidence of bioequivalence. Often the problem is with specific dosage
asis to determine therapeutic equivalence.
; BD (active ingredients and dosage forms with documented bioequivalence
ug delivery); BP (active ingredients and dosage forms with potential
ing drug standard deficiencies); BT (topical products); BX (drug products with
of the same strength has been designated under the same heading. Two or more reference
bioequivalent to each other. †Code B represents drugs that may have been previously assigned
received by the FDA. The therapeutic equivalence of the product may be redetermined after the
Table 3. Examples of Narrow Therapeutic Index Drugs
Therapeutic Class Examples
Antiarrhythmic drugs Digoxin, disopyramide, flecainide, procainamide,
quinidine
Anticoagulant drugs Warfarin
Antiepileptic drugs Carbamazepine, oxcarbazepine, phenytoin,
valproic acid
Antirejection drugs Cyclosporine, everolimus (Afinitor), sirolimus
(Rapamune), tacrolimus
Bronchodilators Theophylline
Mood stabilizers Lithium
Synthetic hormones Ethinyl estradiol, levothyroxinerug P
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biologic is “any virus, therapeutic serum, toxin, antitoxin, or
analogous product applicable to the prevention, treatment or
cure of diseases or injuries of man” (15, p. 6). Biologics are
derived from living sources such as cultures of bacteria, viruses,
or human or animal tissue and may have either a therapeutic or
diagnostic intent. Examples of classes of biologics consist of
recombinant or purified proteins such as cytokines and throm-
bolytic agents, erythropoietin, human growth hormone, mono-
clonal antibodies, blood derivatives, insulin, and vaccines (16).
Biopharmaceuticals differ from traditional small molecule
drugs in that they exhibit a high molecular weight with a
complex 3-dimensional structure, rely on a complex manufac-
turing processes, are produced from living organisms and are
often heterogeneous, and demonstrate significant immuno-
genic safety issues (17,18). Additionally, these agents are
difficult to characterize completely by physicochemical analyt-
ical methods or bioassays, and their biological activity is highly
dependent on the reproducibility of the production process,
manufacturing standards, and maintaining cold chain integrity
(17). Biosimilars, also known as biogenerics, post-patent bio-
logics, and follow-on biologicals, are considered biologic agents
that are copies of a therapeutic protein, not manufactured by an
innovator company, and approved through an abbreviated
process (19).
Whereas traditional small molecule drugs are approved
under the Food, Drug, and Cosmetic Act, most biologics are
approved under the Public Health Service Act (PHSA) (20);
thus, the regulations from the Hatch-Waxman Amendment
do not apply to biologics. Therefore, issues such as bioequiva-
lence and interchangeability as well as innovator exclusivity
periods were initially not addressed. As a part of healthcare
reform, the Biologics Price Competition and Innovation Act
was passed in 2009, amending the PHSA with issues of
biosimilars or biosimilarity. This act defines biosimilarity as
present when: 1) the biological product is “highly similar to the
reference product, notwithstanding minor differences in clini-
cally inactive components”; and 2) “there are no clinically
meaningful differences between the biological product and the
reference product in terms of safety, purity, and potency of the
product” (21, p. 61498). When approving a biosimilar product,
the FDA requires data from analytical, animal, and clinical
studies documenting similarity in safety, purity, and potency;
mechanism of action; prescribing conditions; and route of
administration between the biological product and the refer-
ence product. Interchangeability can occur only when the
biologic product: 1) is considered a biosimilar to the reference
product; and 2) can be expected to produce the same clinical
results as the reference product in any given patient (21).
Additionally, for a product that requires multiple administra-
tions in the same individual, “the risk in terms of safety or
diminished efficacy of alternating or switching between the use
of the biological product and reference product is not greater
than the risk of using the reference product without such
alternation or switch” (21, p. 61498). It is important to
acknowledge, however, that biosimilars do not require dem- aonstration of efficacy and safety in clinical outcome trials;
whether meaningful differences may exist regarding impact on
clinical outcomes is uncertain.
An example of the controversy of biosimilars specific to
patients with cardiovascular disease is the approval of the
first generic low-molecular-weight heparin (LMWH)
enoxaparin in July 2010. In 2008, the FDA recalled several
batches of heparin as a result of increased prevalence of
death from anaphylactoid-type reactions secondary to con-
taminated heparin from over-sulfated chondroitin sulfates
(OSCS), high-molecular-weight dermatan sulfate, and hep-
arin sulfate (22). Because LMWHs are produced using
heparin, OSCS have been detected in batches of LMWHs
(22). Additionally, although generic LMWHs may demon-
strate acceptable molecular weight and anti-Xa profiles, they
can exhibit assay-based differences and immunogenicity
profiles. With these safety issues in mind, as new biosimilars
appear on the market, close pharmacovigilance should be
considered to completely characterize the drug risk profile.
2. Pharmacogenomics
With the completion of the Human Genome Project, ad-
vances in DNA sequencing and genotyping have made it
possible to rapidly and accurately identify variation in DNA
sequence and structure. Correlation between genomic variation
and drug response has allowed for better prediction of individ-
ual responses to specific drugs, optimization for drug selection
and dose, and avoidance of potential medication misadventures
(23). Although used interchangeably, the terms pharmacogenet-
cs and pharmacogenomics are different. Pharmacogenetics is the
nalysis of candidate genes to evaluate the relationship between
ndividual genes and drug effects, whereas pharmacogenomics
s the study of the relationship between variants in a large
ollection of genes across the entire genome to find genetic
ariation that correlates with drug response (23). In the past,
rogress in the field of pharmacogenetics has been hindered by
any social, regulatory, financial, and logistic obstacles. For-
unately, many of these barriers are rapidly disappearing.
resently, genomic testing has begun to move from the bench
o the bedside. For example, chemotherapy decisions using
iologic agents such as trastuzumab (Herceptin) and cetux-
mab (Erbitux) are based on testing for the human epidermal
rowth factor receptor 2 (HER2) and epidermal growth factor
eceptor (EGFR), respectively (17). The commonly used drug
arfarin can be monitored using the international normalized
atio (INR). Dosing can be personalized using genotype data
rom the cytochrome P450 (CYP) 2C9 and vitamin K epoxide
eductase complex subunit 1 (VKORC1) genes (24,25). Using
his genotype data may facilitate selection of the optimal dose
hosen during initiation of warfarin therapy rather than relying
ompletely on frequent measurement of INR, which can be
oth inconvenient and costly. CYP genotyping can also be
sed for selection and monitoring of other drugs, such as
ntidepressants (26).
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September 13, 2011:1287–307 Health Policy Statement: Therapeutic SubstitutionSpecifically addressing cardiovascular pharmacogenetics,
evidence has suggested that inheritance may contribute to
variation in response for drugs used to treat hypertension
and heart failure within and across therapeutic classes. In
the INVEST-GENES (International Verapamil SR-
Trandolapril Study Genetic) study, polymorphisms in
CYP3A5 influenced response to verapamil in blacks and
Hispanics, where the carrier status of the 2 functional alleles
is common (27). The investigators also determined that white
patients with hypertension and coronary artery disease with the
single nucleotide polymorphism (SNP) (rs2357928) in the
CACNB2 gene receiving sustained release verapamil had a
ignificantly increased risk for the first occurrence of all-
ause mortality, nonfatal myocardial infarction, or nonfatal
troke compared with those receiving the beta-blocker
tenolol (28). Beta blockers in heart failure provide impor-
ant lessons regarding class effects. Two formulations of the
ame drug—metoprolol tartrate and metoprolol succinate—
ave very different levels of evidence for improving outcome
n chronic heart failure, with metoprolol succinate having
trong evidence for a major survival benefit (29), whereas
etoprolol tartrate at a different dose is significantly inferior
o the effective carvedilol (30). Contrary to studies with
arvedilol, metoprolol succinate, and bisoprolol in patients
ith heart failure, the BEST (Beta Blocker Evaluation of
urvival Trial) failed to show a significant survival benefit
or patients with systolic dysfunction treated with bucin-
olol, a fourth-generation beta blocker (31,32). When
pecifically analyzing polymorphisms in the beta-adrenergic
eceptor, data from the BEST Genetic substudy suggested
hat improvement in survival and reduction in hospitaliza-
ion was noted only for patients treated with bucindolol who
xpressed the Arg389Arg genotype (33). In contrast, mini-
al benefit was apparent in patients either homozygous or
eterozygous for the Gly389 allele. These results were not
onsidered to be adequate for FDA approval for bucindolol
or genetically determined populations. Moreover, these
ndings were in contrast to the genetic substudy of the
ERIT-HF (Metoprolol Cr/XL Randomized Interven-
ion Trial in Heart Failure) in which the Gly389 allele failed
o confer a significant morbidity and mortality impact in
eart failure patients receiving metoprolol succinate (34).
Similar issues also exist with other medications, including
lopidogrel. Because clopidogrel is expected to be available
s a generic within the next 2 years, many pharmacy benefit
lans may wish to interchange more expensive antiplatelet
gents currently being used, such as prasugrel, with the
eneric clopidogrel. However, patients with a polymor-
hism for CYP2C19, the enzyme responsible for conversion
f clopidogrel (Plavix) to its active metabolite, could exhibit
iminished platelet response to clopidogrel as well as higher
ates of cardiovascular events after acute coronary syndrome
nd percutaneous coronary interventions independent of the
lopidogrel dose (13,35,36). The role of genetic testing to
uide thienopyridine use, however, is uncertain (13). Inaddition, these genomic issues have not been demonstrated
with the novel ADP receptor antagonists, prasugrel (Ef-
fient), or ticagrelor (13,37,38).
Finally, cardiovascular pharmacogenomics data have been
used to predict the risk for adverse events with statins. The
genomewide association Study of the Effectiveness of Addi-
tional Reductions in Cholesterol and Homocysteine
(SEARCH) found a strong correlation of myopathy with the
rs4363657 SNP located within the SLCO1B1 gene in patients
receiving simvastatin 80 mg daily (39). The SLCO1B1 gene
encodes OATP1B1, the solute carrier organic transporter
responsible for the active transport of statins into the hepato-
cyte. About 30% of the study population was either heterozy-
gous or homozygous, whereas only 2% were homozygous for
the variant allele. It has been estimated that the SLCO1B1
variant could account for 60% of statin-induced myopathy
cases in the population (39,40). Dosing of simvastatin should
be individualized in patients who are either homozygous or
heterozygous for this variant allele (40).
It has been estimated that by 2015, a physician may be
able to provide a patient with his or her complete gene
sequencing so as to direct drug therapy (41), although many
challenges remain to generate the evidence needed to
routinely use genetics to guide drug selection and dosing. As
these genomic data become more readily available, pharma-
cists and providers may need to incorporate these data into
their decision analysis when considering therapeutic inter-
change. These data are not only important from a potential
cost-effective approach but also from the standpoint of
patient safety. Based on the evidence presented, blindly
interchanging within and across therapeutic classes when
and if genomic data are available could result in poor clinical
outcomes and potential adverse drug events.
3. Federal Regulations and State Laws
The FDA does not regulate generic substitution, therapeu-
tic interchange, or therapeutic substitution and lacks au-
thority to limit physician prescribing. The FDA’s primary
responsibility is updating information for healthcare provid-
ers, not controlling their decisions (42). On average, the
retail price of a generic drug is 75% lower than the retail
price of a brand-name drug (43). As a result, generic
substitution rates in the United States are almost 90% of the
prescriptions when there is a generic equivalent available
(44). In every state, product substitutions must be made in
accordance with the individual state’s Pharmacy Practice
Act (Appendix 3). As a result, there is variation in require-
ments for when pharmacists can or must dispense generics
among states. In states with a positive formulary approach,
a list of generic drug products from different manufacturers
identifies the products that may be substituted for one
another. Most states specify the Orange Book as the positive
formulary (45). However, the FDA notes that the Orange
Book is not an official, legally binding regulation. The FDA
s
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Health Policy Statement: Therapeutic Substitution September 13, 2011:1287–307explicitly states that the listing of drugs with therapeutic
equivalency constitutes advice and does not mandate which
drug products should be prescribed (1). In states with a
negative formulary approach, drugs are listed for which
substitution by another drug is not allowed. Such may be the
case with narrow therapeutic index drugs. Although the
FDA considers many narrow therapeutic index generics
bioequivalent, some states require that generic versions
cannot be substituted without the prescriber’s consent (44).
In North Carolina, narrow therapeutic index drugs are
required to be refilled using only the same drug product last
dispensed by the same manufacturer unless the prescriber is
notified by the pharmacist prior to dispensing, and the
prescriber and the patient give documented consent (46).
State laws also vary regarding how the final product
selection is determined on the prescription. In the majority
of states, prescribers must expressly indicate by writing
directly on the prescription whether generic substitution is
or is not permitted. Other states include preprinted wording
on the prescription that must be signed or checked to
prevent generic product substitution (47).
The practice of therapeutic interchange by pharmacists is
also allowed in some states (44). Again, the laws regarding
this practice vary widely from state to state, but in all cases,
a preapproved protocol is required. Interchange protocols
can be developed in both an institutional and outpatient
setting as long as a functional formulary system is in place
with an appropriate drug use–setting body.
Finally, the loss of control by individual physicians when
formulary management determines drug choice has led to
speculation that potential serious litigation could arise from
professional activities associated with this practice. Despite
this concern, there have been no successful lawsuits involv-
ing therapeutic interchange (42). In fact, when done appro-
priately, compliance with formulary guidelines set forth by
an institutional pharmacy and therapeutics committee is a
virtually impenetrable shield to liability (42).
4. Therapeutic Approaches
4.1. Therapeutic Interchange
Although the terms therapeutic interchange and therapeutic
ubstitution have been used analogously in the literature,
istinct differences do exist in clinical practice. Many
harmacy and medical organizations have addressed the
ssue of therapeutic interchange (48–53). Interchange can
ccur in which 1 drug is switched for another drug within
he same therapeutic class (e.g., benazepril for lisinopril, or
anitidine for famotidine) or from different classes but with
similar pharmacological effect and potency (e.g., lisinopril
or amlodipine). Environments where therapeutic inter-
hange may occur are in the hospital setting and federal
acilities in which an approved formulary system has been
mplemented, in situations where a collaborative drug man-
gement program between the pharmacist and provider haseen established, or where a contractual arrangement has
een made between a provider and pharmacy benefit plans.
When optimizing pharmacotherapy through therapeutic
nterchange, the approach should incorporate concepts of
oth patient-centered care and interprofessional collabora-
ion. The Institute of Medicine defines patient-centered care
as: “healthcare that establishes a partnership among practi-
tioners, patients, and their families (when appropriate) to
ensure that decisions respect patients’ wants, needs, and
preferences and that patients have the education and sup-
port they need to make decisions and participate in their
own care” (54, p. 7). Health Canada expands on this
definition to include interprofessional collaboration among
healthcare team members. Their definition of collaborative
patient-centered practice promotes the active participation
of each healthcare discipline in patient care though enhanc-
ing patient and family-centered goals and values, providing
mechanisms for continuous communication among caregiv-
ers, optimizing staff participation in clinical decision making
within and across disciplines, and fostering respect for
disciplinary contributions for all professionals (55). De-
pending on the environment, therapeutic interchange
should incorporate input from the patient, potentially their
family, and members of the healthcare team.
4.2. Therapeutic Substitution
In contrast, therapeutic substitution is markedly different than
therapeutic interchange. This strategy occurs without the
prior authorization of the initial prescriber. The use of
therapeutic substitution is rare. This strategy should never
be accepted unless reviewed and approved by the healthcare
team based on the science available.
4.3. Generic Substitution
Generic substitution refers to switching between a branded
drug and its therapeutically equivalent generic version.
Many pharmacy and medical organizations have addressed
this issue, especially as it pertains to generic substitution of
narrow therapeutic index and critical dose drugs (50,56–
64). As highlighted earlier, generic substitution laws are
state specific. In most states, pharmacists cannot substitute
nontherapeutic equivalent products. Some states allow sub-
stitution between products as long as state-specific criteria
are met, such as having the same active ingredient, dosage
form, dose, and route of administration.
5. Issues
5.1. Level of Evidence
The concept of level of evidence plays a central role in
evaluation of data and guideline development. For ACCF/
AHA, the following graded scheme is widely used: Level of
Evidence: A, data derived from multiple randomized clin-
ical trials; Level of Evidence: B, data derived from a single
randomized trial or nonrandomized studies; and Level of
Evidence: C, consensus of experts.
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September 13, 2011:1287–307 Health Policy Statement: Therapeutic SubstitutionLevel of evidence has great implications for the field of
therapeutic interchange. Terms such as equivalence, superi-
ority, noninferiority, pragmatic clinical trials, and comparative
effectiveness require careful evaluation. Studies that use those
statistical terms to evaluate endpoints must be critically
reviewed.
A particularly important concept relates to interpretation
and inference in noninferiority randomized controlled trials.
In comparing drugs or devices in this setting, either a
superiority or a noninferiority design is chosen. In the
former, the objective is to test a new drug versus either
another drug or a placebo with the aim of demonstrating
that the new drug is statistically significantly better than the
comparator. Important considerations include the “power”
to detect the difference between the new drug and the
comparator. The finding of superiority in such a trial is of
great importance.
The other approach is a noninferiority design. This trial
design may either compare a new drug with an older one or
one of a different class or, less frequently, a placebo. It is
intended to demonstrate that the drug of interest is not worse
than the drug with which it is compared. Interpretation of
noninferiority trials is complicated because they rest on iden-
tifying a pre-specified margin within the boundaries of which
it can be concluded that the drug is not worse than its
comparator. It is important to remember that documenting
noninferiority is not the same as documenting equivalence.
The boundaries of this margin are critical; in some studies,
these margins are based on prior studies; in others, an absolute
margin is chosen. For example, the new drug might be deemed
noninferior if the outcome of interest is shown to be no 2%
orse (with 95% confidence) versus the comparator. In other
rials, the margin is based on preserving a certain amount of the
reviously established benefit (e.g., at least 50% of the benefit)
f the comparator with the new drug. FDA guidelines em-
hasize that noninferiority should be identified using both
linical and statistical margins.
Randomized clinical trials of drug research were evalu-
ted by Wangge et al. (65) in 227 articles that reported 232
oninferiority trials. These authors reported that although
7.8% of the trials reported the noninferiority margins, only
5.7% described how the margin was defined. Although
DA guidelines exist for the determination of margins,
10% of the trials documented that the noninferiority
argin was based on appropriate clinical margins. Even
ore troublesome was the finding by these authors that
8% of the trials were interpreted incorrectly.
These issues related to trial design and performances are
xtremely relevant to the field of therapeutic interchange.
his relates to the fact that substitution of 1 drug or a class
f drugs is often based on the assumption that 1 is
oninferior.
5.2. Outpatients and Medication Reconciliation
Therapeutic interchange and generic substitution programs
have been used in the hospital setting for many yearsbecause a single formulary simplifies prescribing decisions as
well as the inventory control process (48). The outpatient or
ambulatory care setting is not as straightforward and pres-
ents its own set of challenges. Care must be taken when
patients transition to and from inpatient and outpatient
settings. During hospitalization, documentation of medica-
tion changes, their rationale, and whether changes are
temporary or permanent is often lacking. As a result, an
estimated 19% to 23% of patients suffer an adverse drug
event after discharge (66).
The American Medical Association strongly recom-
mends that therapeutic interchange in patients with chronic
diseases who are stabilized on a drug therapy regimen be
discouraged (51). However, if a therapeutic interchange is
made during hospitalization, care must be taken to ensure
that the patient is switched back to the home medication at
discharge. If not, therapeutic duplication is possible if the
patient then resumes taking their home medication as well,
which can lead to toxicity and possible adverse effects. In
addition, if a new therapy is initiated in the hospital setting,
there is no guarantee that the same medication will be
continued after discharge. Outpatient drug programs con-
stantly change their formulary, and patients may change
insurance providers and thus be exposed to different formu-
laries (48). Effective transfer of information from the hos-
pitalist to outpatient provider at discharge should include
timely, accurate, and complete documentation of discharge
medications.
5.3. Validation in Quality of Substituted Drug
One of the most persuasive arguments for generic substitu-
tion is cost containment, a critical component of health care.
The 1984 Hatch-Waxman Act authorized the FDA to
approve generic drugs that were demonstrated by the
manufacturer to be bioequivalent (2). The initial test-to-
reference ratio was 75% to 125% but was subsequently
modified to 80% to 125%. The components of this metric
vary on dose administered, gut wall absorption, site of
activity, therapeutic effect, the width of the narrow
therapeutic window, and the ratio of treatment effect to
drug side effects. The definition of biologically equivalent
is therefore of crucial importance and can vary based on
inert binders, manufacturer curves, area under the curve,
as well as the function of time. All of these could have
important implications.
A particularly important issue is that of the prespecified
equivalence of boundaries between the 2 drugs—brand
name versus generic. For this comparison, it must be
remembered that some variability can exist within the
reference product itself. Typically, a prespecified equivalence
of 80% to 125% might be satisfactory to meet the criteria of
equivalence if the risk–benefit ratio is wide. For drugs with
a more narrow risk–benefit ratio, that wide confidence
interval would have important implications for risk or
benefit.
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used for seizure control where small differences of drug
availability or activity may have profound influence on
patient outcome, there is also abundant albeit somewhat
contradictory information in the cardiovascular literature.
An important example of drug selection involves warfa-
rin. Only a few, small prospective randomized controlled
trials including clinical endpoints compared generic and
brand-name warfarin. Whereas some suggest alterations in
INR occur after a switch in medications (67), other reports
indicate no consistent impact on INR after switching from
brand name to generic warfarin (68,69). One large-scale
study of older individuals in Canada demonstrated conver-
sion of 87% of prescriptions to generic medication with no
changes in rates of INR testing, hospitalization for major
hemorrhage, or cerebral thromboembolism (70). Careful
review of the available evidence thus supports the decision
for generic substitution of warfarin with appropriate clinical
oversight and monitoring.
5.4. Class Effect
Drug substitution within the same class of drugs further
increases the complexity of therapeutic interchange.
Whereas with generic substitution therapy, clinical tests
should not be needed when a generic drug is substituted for
a brand name, based upon statistical and clinical analysis
that indicates no difference 20% between the generic and
brand-name drug in terms of safety and efficacy. As men-
tioned before, in drugs with a low or marginal risk–benefit
ratio, this may make a significant difference. This adher-
ence, however, is magnified when there is a substitution of
drugs in the same class. This may have very important
implications.
In this setting, although the 2 drugs may have similar
properties, the end result may be very different. A common
scenario would be substitution of the generic statin, simva-
statin, for atorvastatin (Lipitor). Both are categorized for
use for hyperlipidemia, but both may have additional and
different pleotrophic actions that may affect more than just
the property of reducing LDL cholesterol. In addition, the
side effect of myalgias may also be very different as is the
per-milligram strength of atorvastatin (Lipitor) versus sim-
vastatin. Generic substitution by covered health plans is very
often the result of economic decisions and is heavily driven
by cost. These switches do not put the patient and treating
physician at the center of the decision-making pathway.
Such simple mandated switches from a covered health plan
from atorvastatin (Lipitor) to simvastatin could have major
unintended consequences. Physicians and healthcare per-
sonnel should be cognizant of potential unintended conse-
quences. The patients should also be notified of potential
unintended consequences. If recognized, the physician and
healthcare team should have the opportunity to resolve these
issues in concert with the covered health plan.
Another commonly used class of drugs in patients with
cardiovascular disease are the phosphodiesterase inhibitorsused for erectile dysfunction. All of these drugs are given with
caution in patients with cardiovascular disease, especially when
vasodilators are given concomitantly. However, 1 of the drugs,
vardenafil (Levitra) prolongs QT interval similar to moxifloxa-
cin (Avelox) (71), whereas sildenafil (Viagra) and tadalafil
(Cialis) do not have such a warning in their label. In some
patients, these phosphodiesterase inhibitors might be consid-
ered interchangeable. In cardiac patients, especially those with
risk for QT prolongation or drug-induced torsades de pointes,
interchange may not be advisable.
5.5. Restriction of Drug Availability
This issue has become increasingly complex, involving
several factors including legal, regulatory, equivalence, and
economics. Some of these issues relate to drugs or devices
that can be purchased outside the United States but are not
yet approved in the United States. Some of them are drugs
that are still on patent in the United States but can be
manufactured as generic drugs and purchased in other
countries (e.g., Canada), and some relate to the identical
drugs that are sold at a “discount” in other countries. This is
further complicated by restrictions of institutional formulary
listings, insurance coverage, and sale of drugs online because
they are not available in the United States. One relevant
example is clopidogrel (Plavix), which is manufactured by
sanofi-aventis. This drug has a Class I indication for
patients who receive a drug-eluting stent for treatment of
coronary artery disease. The duration of administration
varies from several months to indefinitely when used to
prevent stent thrombosis. This specific drug is covered by
U.S. patent protection until May 2012. Until recently, there
was no acceptable substitution. The cost of this drug varies
substantially, such that the cost for patients in some areas of
the United States can be as much as $6 per day, which may
not be economically feasible for many patients. A Canadian
company manufactures a generic drug that was priced
approximately 30% lower than Plavix (72) and was sold in
Canada and some pharmacies in New England. Pharmaco-
kinetics reported that this drug met the testing requirements
for a generic drug. However, despite this generic documen-
tation, the drug was barred from sale in the United States.
Other relevant examples include drugs such as dabigatran
and ticagrelor, both of which had advantages as antithrom-
botic agents available in Europe before FDA approval in the
United States. It is important to highlight that the Federal
Food, Drug, and Cosmetic Act prohibits persons from
importing into the United States any prescription medica-
tion that has not been approved by the FDA for sale (73).
However, the FDA has developed specific guidelines for
coverage of personal importations with respect to the
personal use of unapproved drugs (74).
The FDA may allow for an individual entering into the
United States to import no more than a 3-month supply of
an unapproved drug if all the following conditions are met:
the intended use of the drug is for a serious condition in
which effective treatment is not found domestically; the
perm
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present an unreasonable risk; and the individual has in
writing a statement that the drug is for his or her own
personal use and provides the name and address of the
licensed physician in the United States responsible for his or
her treatment with the drug (74). Export of larger quantities
is illegal. The issue of new as well as generic drugs not
available in the United States but available in the rest of the
world is apt to increase as worldwide manufacturing facili-
ties become more widely available.
6. Specific Populations
There are other very important groups of patients in which
therapeutic interchange/substitution may have markedly
adverse consequences. In these groups, the risk–benefit ratio
of every therapeutic interchange/substitution needs to be
carefully reviewed, taking into consideration the specific
drug and the specific patient or clinical setting on a
case-by-case basis.
6.1. Elderly Patients
Elderly patients in the United States (defined as 65 years
of age) are the most likely to have chronic medical and
especially cardiovascular conditions that require treatment.
More than 80% of elderly patients take at least 1 medication
every day and, as a group, consume one third of all
prescribed drugs (75). The physiological effects of aging on
pharmacokinetics affect the absorption, distribution, metab-
olism, and elimination of drugs, but these changes have
considerable individual variability and are hard to predict.
Nonetheless, characteristics of older patients that predispose
them to adverse drug effects or sensitize them to drug effects
include a greater severity of illness, multiple comorbidities,
smaller body size (especially for women), and lower rates of
hepatic and renal metabolism and excretion (75).
Little information is available specifically about substituting
medications in the elderly. Even for clinical trials designed
specifically to examine older adults, limited enrollment of
Figure 2. Results of Meta-Analyses of Trials Comparing Classes o
ACE indicates angiotensin-converting enzyme; and CI, confidence interval. Reprinted withselectively higher functioning subjects makes subsequent gen-eralizations about study findings problematic. For example, in
SHEP (Systolic Hypertension in the Elderly Program), only
1% of screened persons were enrolled, and 95% of those were
living independently (76). Thus, most information about drug
substitutions is derived from studies that did not enroll large
numbers of older patients. In a comprehensive meta-analysis of
studies comparing treatment with cardiovascular brand-name
drugs with generic drugs, essentially no differences in effect size
were seen for beta blockers, diuretics, calcium channel blockers,
antiplatelet agents, ACE inhibitors, statins, alpha blockers, or
warfarin (Figure 2) (77). Although the findings provide some
reassurance about the relative equivalence of generic medica-
tions, the number of subjects in each study was small, and the
extrapolation to older individuals cannot be made with certainty.
Caution and monitoring are indicated in prescribing
medications to older patients. Risks of adverse consequences
could be minimized by avoiding strict adherence to pre-
scribing guidelines; knowing the pharmacology of the drugs
prescribed; limiting the number of drugs prescribed; deter-
mining the dosage based on an individual patient’s overall
condition and comorbidities—generally starting at lower
doses; and importantly, surveying effectiveness and untow-
ard effects, particularly after the transition from an in-
hospital to outpatient setting (75).
6.2. Pediatric Patients
The Committee on Drugs of the American Academy of
Pediatrics published their initial Policy Statement on Generic
Prescribing, Generic Substitution, and Therapeutic Substitu-
tion in 1987 (78) and reaffirmed it in 2009 (79). Based on the
lack of evidence supporting the assumption of bioequivalence
for most therapeutic agents in infants and children, the
Committee did not support a blanket recommendation for
generic substitution. They also strongly opposed any attempt
to allow the practice of therapeutic substitution. Therapeutic
interchange was not specifically addressed.
This conservative position is largely based on the fact that
much of what we know regarding the pharmacokinetics,
pharmacogenomics, efficacy, and safety of many drugs in
eric and Brand Name Drugs Used for Cardiovascular Conditions
ission from Kesselheim et al. (77). Copyright 2008 American Medical Association.f Genchildren is extrapolated from the adult experience. Applying
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tal systems of adult origins may have limited applicability to
pediatric disease. This has been highlighted in a review
examining tacrolimus pharmacokinetic and pharmacog-
enomic differences between adult and pediatric transplant
recipients (80). Inherent physiological differences exist in
the young child, including less effective plasma binding
proteins, altered expression of intestinal P-glycoprotein, and
increased expression of phase 1 metabolizing enzymes,
resulting in clinically significant differences when adminis-
tering tacrolimus to a child (80).
Recent data demonstrate that only 25% of approved drugs
marketed in the United States have adequate pediatric data
to support approval of product labeling by FDA for dosing,
safety, or efficacy in children (81). It was not until 1994 that
a series of legislative changes targeted improved drug
therapy in children of all ages. In that year, the FDA
Pediatric Rule provided an avenue for manufacturers to
insert information pertaining to the clinical pharmacology
and therapeutic use of drugs in pediatric patients into
approved product labeling (82). The FDA Modernization
Act of 1997 then provided an incentive for the pharmaceu-
tical industry to complete pediatric studies of marketed drug
products. This Pediatric Exclusivity Provision provided an
additional 6 months of patent protection, or marketing
exclusivity, in return for performing studies specified by the
FDA (81). The Best Pharmaceuticals for Children Act of
2002 and the Food and Drug Amendments Act of 2007
extended the economic incentives provided by pediatric
exclusivity. In the 10 years since the start of the program in
1997, 115 products had a labeling change. Approximately
one third of these labeling changes showed an important
difference in the pediatric dosing, safety, or efficacy com-
pared with adult patients that will likely result in long-term
health benefits for children (81). In September 2010, the
National Institute of Child Health and Development
awarded a contract to establish a Pediatric Trials Network
to provide an environment and an appropriate infrastructure
for conducting safe and effective pediatric clinical trials for
the Best Pharmaceuticals for Children Act.
Despite the relative paucity of data, the practices of
generic substitution and therapeutic interchange are recog-
nized and accepted in many pediatric healthcare settings.
Based on pharmacological equivalence, clinical evidence,
cost, medical staff involvement, and opportunity for vari-
ance, institutional drug–setting bodies such as pharmacy
and therapeutic committees identify therapeutic classes
amenable to interchange, and update based on the evolving
literature. Contrary to adults, the number of drug classes
and agents chosen for therapeutic interchange in pediatric
patients is much more limited. Common cardiovascular
classes of drugs selected for interchange in adult patients
may include statins, ACE inhibitors, angiotensin receptor
blockers, calcium channel blockers, and beta-adrenergic
blocking agents (43). In contrast, only statins may be opermitted to be interchanged within class in pediatric
patients (83).
6.3. Female Patients
Selecting cardiovascular medications for women requires
additional and sometimes different considerations compared
with prescribing for men. Pharmacodynamic differences
exist for women related to lower weight, lower volume of
distribution, and lower renal drug clearance in women (84).
n addition, sex-based prolongation of the QT interval
arrants caution in the prescription of cardiovascular and
oncardiovascular drugs that may potentially prolong the
T interval and lead to serious arrhythmias. Other cardio-
ascular drug-related adverse effects more common in
omen include hemorrhagic complications of anticoagu-
ants and antiplatelet drugs, electrolyte abnormalities with
iuretics, myopathy with statins, and cough with ACE
nhibitors (84). A specific example relates to the use of
igoxin. In a post hoc analysis of the Digitalis Investigation
roup (DIG) trial, there was a suggestion that digoxin use
as associated with an increased risk of mortality in women
ith heart failure and a left ventricular ejection fraction
45% compared with men (85). These poor outcomes have
een related to the fact that these women exhibited higher
igoxin serum concentrations, possibly because of the drug–
rug interaction between hormone replacement and digoxin
86). In addition, because serum creatinine was used to
alculate the digoxin dose, serum creatinine may not be a
ood marker of chronic kidney disease in women (87).
Initial therapeutic decisions are also complicated by the
act that the evidence base for medication effectiveness in
omen is limited. Most randomized clinical trials (with few
otable exceptions) (88) have enrolled a minority of women,
hus limiting generalizability of the findings to women. It is
lso worth mentioning that many manufacturers purpose-
ully avoid the study of women of childbearing age to limit
heir legal liability, not because of scientific issues as the
rimary concern. When studied specifically in women, sex
ifferences in outcomes are apparent. For example, the use
f aspirin was not effective in lowering cardiovascular
utcomes in women 65 years of age who were not at high
isk for stroke in the Women’s Health Study (89). Whether
his is a differential effect of ASA on outcome by sex among
rimary prevention patients or whether the effect was
elated to baseline risk is unclear. Thus, general principles of
ndividualized drug and dose selection, careful monitoring
f intended effect and side effects with initial drug and
specially after drug substitution, and minimizing total
umber of medications should be adhered to for women.
Pregnancy also requires heightened considerations about
rug selection for both the mother and fetus. A number of
lterations occur during pregnancy that may influence the
vailability, elimination, action, and side effect profile of
edications. Absorption and bioavailability of drugs may
ary with intestinal motility and acid secretion during stages
f pregnancy. Hemodynamic changes with gestation affect
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elimination because of increased cardiac output. Treatment
of any condition with drugs that were at steady state prior to
pregnancy will require reassessment for efficacy and adverse
effects throughout pregnancy. In addition, the interface of
the placenta and fetus impacts drug transmission to the fetus
and must always be considered in deciding the choice and
dose of a drug to be used for maternal conditions during
pregnancy (90). Other considerations include the fact that
drug selection for women of child-bearing age must account
for the possibility of unplanned pregnancies and early,
undetected pregnancy that could unknowingly expose the
developing fetus to pharmaceutical agents (91).
6.4. Immunocompromised Patients
Immunocompromised patients, including those who have
received organ transplants, are at high risk of drug interac-
tions because of the multiple drugs required for chronic
administration to prevent rejection, treat the underlying
condition, treat or prevent infection, and treat or prevent
many comorbid conditions. Knowledge of all agents, spe-
cifically regarding their pharmacokinetics and therapeutic
equivalency, is required to minimize adverse drug reactions
and drug–drug interactions (92). For example, cyclosporine
is marketed as oil-base (Sandimmune) and modified, mi-
croemulsion (Gengraf and Neoral) formulations. Although
Gengraf and Neoral are therapeutically equivalent and can
be interchanged, neither product can be interchanged with
Sandimmune (1). Potential interchange of Sandimmune for
either Gengraf and Neoral could result in significantly
erratic cyclosporine blood concentrations (58). Concern also
exists when generic-to-generic switches occur with immu-
nosuppressants. As of 2011, 4 generic oral tacrolimus and 11
oral mycophenolate mofetil products are on the market with
bioequivalency ratings of AB (1). The effect of such switches
between generics on serum drug concentrations and patient
outcomes remains unknown.
6.5. Acute Coronary Syndrome Patients
Acute coronary syndromes (ACS) are frequent, and patients
with these conditions are often treated with multiple med-
ications, raising the potential not only for drug-drug inter-
actions, but also the potential for multiple therapeutic
interchange/substitution episodes. Commonly used drugs in
this setting include glycoprotein IIb/IIIa inhibitors and
LMWHs.
6.5.1. Glycoprotein IIb/IIIa
In the former group, there are several drugs including the
antibody fragment abciximab, and the small molecules
tirofiban and eptifibatide all inhibit the platelet glycoprotein
IIb/IIIa receptor (93,94). Some hospitals may only have 1 or2 available for clinical use on the formulary. The drugs,
however, are very different, based on their structure, metab-
olism, and effect on outcomes in patients treated with
percutaneous coronary intervention or for acute coronary
syndromes (93). Eptifibatide, for example, has been suscep-
tible to overdosing in patients with reduced renal function
(95). There is a specific, well-known relationship between
creatinine clearance and these drugs. This relationship
affects selection and dosing to be ordered. Healthcare
providers in individual practices should be aware of these
differences and base treatment strategies on the availability
of specific drugs, altering strategies as appropriate.
6.5.2. Anticoagulants
Anticoagulants are also used ubiquitously. These include
LMWH, unfractionated heparin, bivalirudin (Angiomax),
and fondaparinux (Arixtra). The specific use of each of these
depends upon multiple factors, including patient factors,
timing of administration, and specific drugs available. They
are not interchangeable. For example, bivalirudin has been
approved for percutaneous coronary intervention procedures
but not as a part of routine medical care of unstable angina.
Although fondaparinux can be used during percutaneous
coronary intervention, it must be combined initially with
another anticoagulant with at least factor IIa activity. Such
a therapeutic strategy avoids thrombus formation in the
catheters (96). A number of LMWHs are available; these
have often been subject to therapeutic substitution based
largely on economic considerations (97). Although there
have been a large number of clinical trials to define which
agents (and doses) have the strongest evidence for various
clinical conditions, healthcare providers have been pressured
by many hospitals to use a single agent to qualify for
reduced purchasing costs. As previously mentioned, spe-
cific LMWHs, as well as generic LMWH, may exhibit
assay-based differences and immunogenicity profiles. Ac-
cordingly, healthcare teams need to be vigilant about
therapeutic interchange in this patient group.
6.5.3. Antiplatelet Agents
Antiplatelet agents are an essential component of care in
this setting. Clopidogrel (Plavix) has been a cornerstone. As
previously mentioned, there is an abundant amount of data
on the pharmacogenomics and pharmacodynamics of clopi-
dogrel administration (13). This has the potential to affect
safety and outcome, although complete resolution of this
question has not been reached. Options in selected centers
include the substitution of newer drugs; for example, pra-
sugrel, although the risk–benefit ratio of these newer agents
may be different from clopidogrel because of the marked
increase in bleeding if administered to patients with a very
small body weight, those 75 years of age, or patients with
prior stroke. Such considerations must be taken into account
if therapeutic interchange is considered in this setting.
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Fibrinolytic agents have been used for reperfusion therapy of
ACS patients with ST-segment elevation myocardial infarc-
tion and are still indicated in patients who do not have
prompt access to catheterization laboratories. Fortunately,
large-scale head-to-head comparison studies have evaluated
the relative strengths of these agents that differ widely in
chemical structure, antigenicity, and administration. Some
of these head-to-head trials have documented clinical supe-
riority of a specific fibrinolytic agent. For example, tissue-
type plasminogen activator has been shown to be superior to
streptokinase. However, in many hospital settings, only a
limited number of these agents are available. This has
important implications. Only tissue-type plasminogen acti-
vator is approved for use in acute ischemic stroke. The safety
and efficacy of other fibrinolytic agents for the treatment of
acute ischemic stroke have not been demonstrated, and
experimental protocols that have translated the standard
dosing for acute myocardial infarction to the treatment of
acute ischemic stroke have resulted in excessive rates of
intracranial hemorrhage. Accordingly, in some institutions,
tissue-type plasminogen activator may be the only option
available.
6.5.5. Proton Pump Inhibitors
Proton pump inhibitors are widely used in this setting to
minimize the potential for gastrointestinal bleeding. They
have been the object of therapeutic substitution to enable
purchasing agreements or switch to less expensive alterna-
tives, by hospitals and in outpatient settings (98), with
mixed success. Given observations regarding differential
effects on drug metabolism enzymes, such as CYP2C19, it
is possible that such substitutions could have unintended
consequences (13). There has been concern that rates of
subsequent stent thrombosis may be affected in patients
treated with clopidogrel who also are given a proton pump
inhibitor. These potential effects of coadministration of 1
specific proton pump inhibitors and clopidogrel on sub-
sequent stent thrombosis are of great importance. This
has implications for the use of alternative antiplatelet
strategies as well as alternative strategies to minimize
gastrointestinal bleeding based upon the risk profile of
the specific patient (13).
These examples of clinical settings in patient populations
are representative of the crucial importance of patient
characteristics, clinical presentation, comorbid conditions,
and specific drug regimens selected that must be considered
in selecting specific therapeutic strategies. They emphasize
the critical nature of the team care approach to patients,
with involvement of cardiologists, nursing staff, and phar-
macologists to match the correct drug and correct dose with
the correct patient and clinical situation to optimize out-
come. Such a team approach has been emphasized by the
Institute of Medicine to minimize medical errors and
optimize outcome.7. Recommendations
1. Therapeutic substitution and therapeutic interchange
refer to 2 distinctly different practices. Therapeutic
substitution should not be accepted. When considering
therapeutic interchange, third-party payers must take
into account multiple factors when approving the inter-
change such as level and strength of evidence for the
medication and the patient’s specific medical condition.
Cost should be a consideration in this decision but not be
the primary factor.
2. Each healthcare facility should have a formally chartered
interdisciplinary pharmacy and therapeutics committee
charged with ensuring medication safety and developing
an evidence-based formulary. The committee’s charge
should include the development of policy for therapeutic
interchange/substitution. Decisions and recommenda-
tions should be reviewed at least annually to address new
evidence as it becomes available.
3. All formulary decisions should be made based primarily on
the recommendations of the healthcare team after consid-
ering the scientific evidence in the specific patient or patient
groups to be treated and the ratio of risk/balance in that
setting. These decisions should be widely and proactively
promulgated to prescribing physicians and include provi-
sions for appeals both at the policy level and for individual
patient exceptions. Economic considerations, although of
substantial importance, should only be addressed after those
other considerations have been fully evaluated.
4. All payers that consider instituting a therapeutic inter-
change policy should ensure that all healthcare teams
have the information necessary, as outlined in this
document, to provide guidance to prescribing physicians.
Such guidance should be proactively given so that it is
available at the point of care.
5. After initiating a therapeutic interchange policy, health-
care systems are responsible for implementing processes
for informing individual patients of the change in med-
ications prescribed.
6. Applicable state, federal, and international policies con-
cerning metrics of equivalence, manufacturing, packag-
ing, and purity need to be monitored annually, at
minimum. These policies should be followed by the
pharmacy and therapeutics committee with the appear-
ance of new formulations or generics on the market and
when issues surrounding product manufacturing, pack-
aging, and purity are reported by specific manufacturers
or the FDA. It is very important for healthcare teams to
have full and timely access to measures of bioequivalence
in generic drugs.
7. Pharmacists must understand both the rationale for
and use of the Orange Book. Contemporary pharmacy
practice requires confirmation that a substituted ge-
neric drug is bioequivalent to the prescribed product.
At the state level, policymakers overseeing generic
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tions and recommend pharmacists use the Orange Book
in determining whether bioequivalence has been doc-
umented between the generic medication and the
prescribed product. When dispensing medications for
chronic conditions, a pharmacist should communicate
to the patient both verbally and in writing (e.g., on the
label of the prescription bottle) when a medication’s
manufacturer has changed. This is of particular im-
portance when dispensing a narrow therapeutic index/
critical dose medication.
. Pharmacogenomics may have a substantial impact on the
field in the future. As scientific data and evidence
continue to emerge and technologies improve, policies
should be adapted as needed. This may enhance the
ability to personalize medical care for the individual
patient.
. Special groups of patients with unique requirements,
such as immunocompromised patients, pediatric pa-
tients, women—particularly those who are pregnant—or
the elderly who require multiple medications in the
setting of acute or chronic illness, should be given special
consideration before therapeutic interchange is imple-
mented. This is of significant importance when drugs
that have a narrow therapeutic/toxicity ratio are being
administered or considered.
ACCF President and Staff List
David R. Holmes, Jr., MD, FACC, President
John C. Lewin, MD, Chief Executive Officer
Janet Wright, MD, FACC, Senior Vice President, Science
and Quality
Charlene L. May, Senior Director, Science and Clinical
Policy
Dawn R. Phoubandith, MSW, Director, ACCF Clinical
Documents
Erin A. Barrett, MPS, Senior Specialist, Science and
Clinical Policy
REFERENCES
1. U.S. Food and Drug Administration. Orange Book: Approved Drug
Products With Therapeutic Equivalence Evaluations. 2011. Available
at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Ac-
cessed February 6, 2011.
2. Drug Price Competition and Patent Term Restoration Act of 1984.
Public Law 98-417 (S 1538).
3. Chen ML, Straughn AB, Sadrieh N, et al. A modern view of excipient
effects on bioequivalence: case study of sorbitol. Pharm Res. 2007;24:
73–80.
4. Dannenfelser RM, He H, Joshi Y, et al. Development of clinical
dosage forms for a poorly water soluble drug I: application of
polyethylene glycol-polysorbate 80 solid dispersion carrier system.
J Pharm Sci. 2004;93:1165–75.
5. Jackson K, Young D, Pant S. Drug-excipient interactions and their
affect on absorption. Pharm Sci Technolo Today. 2000;3:336–45.
6. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and
innovator drugs: a review of 12 years of bioequivalence data from the
United States Food and Drug Administration. Ann Pharmacother.
2009;43:1583–97.7. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequiva-
lence: an FDA regulatory overview. Pharm Res. 2001;18:1645–50.
8. Guidance for industry: bioavailability and bioequivalence studies for
orally administered drug products—general considerations. 2003.
Available at: http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/UCM070124.pdf. Ac-
cessed February 6, 2011.
9. Schuirmann DJ. A comparison of the two one-sided tests procedure
and the power approach for assessing the equivalence of average
bioavailability. J Pharmacokinet Biopharm. 1987;15:657–80.
10. Tam SW, Sabolinski ML, Worcel M, et al. Lack of bioequivalence
between different formulations of isosorbide dinitrate and hydralazine
and the fixed-dose combination of isosorbide dinitrate/hydralazine:
the V-HeFT paradox. Clin Pharmacokinet. 2007;46:885–95.
11. Buehler GJ. History of Bioequivalence for Critical Dose Drugs. 2010.
Available at: http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/AdvisoryCommitteefor
PharmaceuticalScienceandClinicalPharmacology/UCM209319.pdf.
Accessed February 6, 2011.
12. Summary minutes of the Advisory Committee for Pharmaceutical
Science and Clinical Pharmacology. 2010. Available at:
http://www.fda.gov/downloads/AdvisoryCommittees/Committees
MeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuti
calScienceandClinicalPharmacology/UCM210930.pdf. Accessed Feb-
ruary 6, 2011.
13. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel
clinical alert: approaches to the FDA “boxed warning”: a report of the
American College of Cardiology Foundation Task Force on Clinical
Expert Consensus Documents and the American Heart Association.
J Am Coll Cardiol. 2010;56:321–41.
14. Ledford H. ‘Biosimilar’ drugs poised to penetrate market. Nature.
2010;468:18–9.
15. U.S. Food and Drug Administration Department of Health and
Human Services. Food and drugs. Ch.1, subch. F, Biologics. Fed
Regist. 2010.
16. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related
regulatory actions for biologicals approved in the United States and the
European Union. JAMA. 2008;300:1887–96.
17. Lacana E, Amur S, Mummanneni P, et al. The emerging role of
pharmacogenomics in biologics. Clin Pharmacol Ther. 2007;82:466–71.
18. Frank RG. Regulation of follow-on biologics. N Engl J Med.
2007;357:841–3.
19. Hennessy S, Leonard CE, Platt R. Assessing the safety and compar-
ative effectiveness of follow-on biologics (biosimilars) in the United
States. Clin Pharmacol Ther. 2010;87:157–9.
20. Public Health Service Act, USC 42. U.S. Food and Drug Adminis-
tration. 2009.
21. U.S. Food and Drug Administration. Approval pathway for biosimilar
and interchangeable biological products; public hearing; request for
comments. Fed Regist. 2010;75:61497–501.
22. Kalodiki E, Fareed J. New and generic anticoagulants and biosimilars:
safety considerations. Clin Appl Thromb Hemost. 2011;17:136–9.
23. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics:
challenges and opportunities. Ann Intern Med. 2006;145:749–57.
24. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of
response to warfarin during initial anticoagulation. N Engl J Med.
2008;358:999–1008.
25. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin
dose with clinical and pharmacogenetic data. N Engl J Med. 2009;
360:753–64.
26. Matcher DB, Thakur ME, Grossman I, et al. Testing for Cytochrome
P450 Polymorphisms in Adults With Non-Psychotic Depression
Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). (Pre-
pared by the Duke Evidence-based Practice Center under Contract
No. 290-02-0025). Rockville, Md: Agency for Healthcare Research
and Quality; 2007. AHRQ Publication No. 07-E002 ed.
27. Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5
polymorphisms with hypertension and antihypertensive response to
verapamil. Clin Pharmacol Ther. 2007;81:386–91.
28. Niu Y, Gong Y, Langaee TY, et al. Genetic variation in the beta2
subunit of the voltage-gated calcium channel and pharmacogenetic
association with adverse cardiovascular outcomes in the INternational
VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-
GENES). Circ Cardiovasc Genet. 2010;3:548–55.
44
4
4
5
5
5
5
5
5
5
5
1302 Holmes et al. JACC Vol. 58, No. 12, 2011
Health Policy Statement: Therapeutic Substitution September 13, 2011:1287–30729. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF). Lancet. 1999;353:2001–7.
30. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with chronic
heart failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet. 2003;362:7–13.
31. A trial of the beta-blocker bucindolol in patients with advanced
chronic heart failure. N Engl J Med. 2001;344:1659–67.
32. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 compre-
hensive heart failure practice guideline. J Card Fail. 2010;16:e1–194.
33. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymor-
phism within a conserved beta(1)-adrenergic receptor motif alters
cardiac function and beta-blocker response in human heart failure.
Proc Natl Acad Sci U S A. 2006;103:11288–93.
34. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1
adrenergic receptor Arg389Gly polymorphism in individuals with
heart failure: a MERIT-HF substudy. Eur J Heart Fail. 2003;5:463–8.
35. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymor-
phisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.
36. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of
cytochrome P450 2C19 genotype with the antiplatelet effect and
clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849 –57.
37. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic
polymorphisms and the response to prasugrel: relationship to pharma-
cokinetic, pharmacodynamic, and clinical outcomes. Circulation.
2009;119:2553–60.
38. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation
between CYP2C19 genotype and pharmacodynamics in patients treated
with ticagrelor versus clopidogrel: the ONSET/OFFSET and RE-
SPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–66.
39. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-
induced myopathy—a genomewide study. N Engl J Med. 2008;359:
789–99.
40. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med.
2008;359:856–8.
41. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics
and individualized drug therapy. Nat Rev Cardiol. 2009;6:632–8.
42. Brushwood DB. Legal issues surrounding therapeutic interchange in
institutional settings: an update. Formulary. 2001;36:796–804.
43. Congressional Budget Office. Effects of using generic drugs on
Medicare’s prescription drug spending. Washington, DC: Congres-
sional Budget Office; 2010. Publication No. 4043.
44. Assistant Secretary for Planning and Evaluation Staff. ASPE issue
brief: expanding the use of generic drugs. Washington, DC: U.S.
Department of Health and Human Services, 2010.
45. Generic Drugs: A Law CE. Pharmacist’s Letter. Course No. 36. 2006.
Available at: http://pharmacistsletter.therapeuticresearch.com/ce/
ceCourse.aspx?pc06-36. Accessed June 22, 2011.
6. Crowther B, Munoz M. The skinny on narrow therapeutic index drugs
used in transplantation: a brand vs. generic debate. Presented at the
University of Texas at Austin College of Pharmacy, January 29, 2010;
San Antonio, TX. Available at: http://www.utexas.edu/pharmacy/
divisions/pharmaco/rounds/01-29-10.pdf. Accessed April 27, 2011.
7. Piepho RW. Therapeutic interchange and equivalence: focus on
antihypertensive agents: substitution at the pharmacy level. 2011.
Available at: http://www.medscape.org/viewarticle/416390_4. Ac-
cessed February 7, 2011.
8. Gray T, Bertch K, Galt K, et al. Guidelines for therapeutic inter-
change—2004. Pharmacotherapy. 2005;25:1666–80.
9. Academy of Managed Care Pharmacy. Therapeutic interchange. 2003.
Available at: http://www.amcp.org/amcp.ark?pAA46FF1F. Ac-
cessed February 6, 2011.
0. American Society of Health System Pharmacy. Principles of a sound
drug formulary system. 2006. Available at: http://www.ashp.org/
DocLibrary/BestPractices/FormEndPrinciples.aspx. Accessed Febru-
ary 6, 2011.
1. American Medical Association. Report 2 of the Council on Science
and Public Health (A-04): impact of drug formularies and therapeutic
interchange on health outcomes. 2004. Available at: http://www.ama-
assn.org/resources/doc/csaph/a04csa2-fulltext.pdf. Accessed February
6, 2011.
2. Therapeutic substitution and formulary systems. American College of
Physicians. Ann Intern Med. 1990;113:160–3.3. American Society of Consultant Pharmacists. Guidelines for imple-
menting therapeutic interchange in long-term care. 1997. Available at:
http://www.ascp.com/resources/policy/upload/Gui97-Therapeutic%
20Interchange.pdf. Accessed February 6, 2011.
4. Institute of Medicine. Envisioning the National Health Care Quality
Report. Washington, DC: National Academy Press; 2001.
5. Oandasan I, D’Amour D, Zwarenstein M, et al. Interdisciplinary
education for collaborative, patient-centred practice: research and
findings report. February 20, 2004. Ottawa, Canada: Health Canada,
2004.
6. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society
of Transplantation conference on immunosuppressive drugs and the
use of generic immunosuppressants. Am J Transplant. 2003;3:1211–5.
7. American Medical Association. Report 2 of the Council on Science
and Public Health (A-07): generic substitution of narrow therapeutic
index drugs. 2007. Available at: http://www.ama-assn.org/resources/
doc/csaph/csaph2a07-fulltext.pdf. Accessed February 6, 2011.
58. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in
transplantation: a National Kidney Foundation White Paper. Am J
Kidney Dis. 1999;33:389–97.
59. Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immuno-
suppression in thoracic transplantation: an ISHLT educational advi-
sory. J Heart Lung Transplant. 2009;28:655–60.
60. American Academy of Neurology. Position statement on the coverage
of anticonvulsant drugs for the treatment of epilepsy. 2006. Available
at: http://www.aan.com/globals/axon/assets/2648.pdf. Accessed Feb-
ruary 6, 2011.
61. Academy of Managed Care Pharmacy. Narrow therapeutic index
(NTI) drugs, interchange of. 2004. Available at: http://
www.amcp.org/amcp.ark?pAA3B226A. Accessed February 6, 2011.
62. Academy of Managed Care Pharmacy. Generic drugs. 2010. Available
at: http://www.amcp.org/amcp.ark?pAA2D6237. Accessed Febru-
ary 6, 2011.
63. American Thyroid Association. AACE, TES and ATA joint position
statement on the use and interchangeability of thyroxine products.
2004. Available at: https://www.aace.com/sites/default/files/AACE-
TES-ATA-ThyroxineProducts.pdf. Accessed February 6, 2011.
64. Generic Pharmaceutical Association. Authorized generics. 2010.
Available at: http://www.gphaonline.org/issues/authorized-generics.
Accessed February 6, 2011.
65. Wangge G, Klungel OH, Roes KC, et al. Interpretation and inference
in noninferiority randomized controlled trials in drug research. Clin
Pharmacol Ther. 2010;88:420–3.
66. Cua YM, Kripalani S. Medication use in the transition from hospital
to home. Ann Acad Med Singapore. 2008;37:136.
67. Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and
decreased international normalized ratio response after nationwide
generic switching. Clin Pharmacol Ther. 2003;74:215–21.
68. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch
from a branded to a generic warfarin sodium product: an observer-
blinded, randomized, crossover study. Clin Ther. 2005;27:309–19.
69. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and
generic warfarin interchangeable? Multiple n-of-1 randomized, cross-
over trials. Ann Pharmacother. 2005;39:1188–93.
70. Paterson JM, Mamdani M, Juurlink DN, et al. Clinical consequences
of generic warfarin substitution: an ecological study. JAMA. 2006;296:
1969–72.
71. Arizona Center for Education and Research on Therapeutics. Drugs
with possible risk of torsades de pointes. 2011. Available at: http://
www.azcert.org/medical-pros/drug-lists/l ist-02.cfm?sort
Generic_name. Accessed April 10, 2011.
72. Planet Drugs Direct home page. 2011. Available at: http://
www.planetdrugsdirect.com/. Accessed February 25, 2011.
73. U.S. Customs and Border Protection. Medication/drugs. 2011. Avail-
able at: http://www.cbp.gov/xp/cgov/travel/clearing/restricted/
medication_drugs.xml. Accessed May 11, 2011.
74. U.S. Customs and Border Protection. FDA Enforcement Policy
Regarding the Personal Importation of Violative Drugs. 2011. Avail-
able at: http://www.cbp.gov/xp/cgov/travel/clearing/restricted/
medication_drugs.xml. Accessed May 19, 2011.
75. Beyth RJ, Shorr RI. Principles of drug therapy in older patients:
rational drug prescribing. Clin Geriatr Med. 2002;18:577–92.
76. SHEP Cooperative Research Group. Prevention of stroke by antihy-
pertensive drug treatment in older persons with isolated systolic
77
7
8
8
8
8
8
8
8
8
8
8
9
9
9
9
9
9
9
9
9
9
D
(
J
C
G
f
r
1303JACC Vol. 58, No. 12, 2011 Holmes et al.
September 13, 2011:1287–307 Health Policy Statement: Therapeutic Substitutionhypertension: final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA. 1991;265:3255–64.
7. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of
generic and brand-name drugs used in cardiovascular disease: a
systematic review and meta-analysis. JAMA. 2008;300:2514–26.
8. American Academy of Pediatrics Committee on Drugs: Generic
prescribing, generic substitution, and therapeutic substitution. Pediat-
rics. 1987;79:835.
9. American Academy of Pediatrics. AAP publications retired and
reaffirmed. Pediatrics. 2009;123:188.
0. Kwaku M, Altshuler J, Lu A. Tacrolimus pharmacokinetics and
pharmacogenomics differences between adults and pediatric solid
organ transplant recipients. Pharmaceutics. 2010;2:291–9.
1. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of
clinical trials performed under the pediatric exclusivity program.
JAMA. 2007;297:480–8.
2. Leeder JS, Kearns GL. The challenges of delivering pharmacogenom-
ics into clinical pediatrics. Pharmacogenomics J. 2002;2:141–3.
3. Children’s National Medical Center Pharmacy and Therapeutics
Committee. Therapeutic Interchange: Procedure CHPC: M:42p.
Internal procedure in possession of Jeffrey Becker, M.D. 2011.
4. Schwartz JB. Gender-specific implications for cardiovascular medica-
tion use in the elderly optimizing therapy for older women. Cardiol
Rev. 2003;11:275–98.
5. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the
effect of digoxin for the treatment of heart failure. N Engl J Med.
2002;347:1403–11.
6. Adams KF Jr., Patterson JH, Gattis WA, et al. Relationship of serum
digoxin concentration to mortality and morbidity in women in the
Digitalis Investigation Group trial: a retrospective analysis. J Am Coll
Cardiol. 2005;46:497–504.
7. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration
and outcomes in women with heart failure: a bi-directional effect and
a possible effect modification by ejection fraction. Eur J Heart Fail.
2006;8:409–19.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium
antagonist vs a non-calcium antagonist hypertension treatment strat-
egy for patients with coronary artery disease: the International
Verapamil-Trandolapril Study (INVEST): a randomized controlled
trial. JAMA. 2003;290:2805–16.
9. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose
aspirin in the primary prevention of cardiovascular disease in women.
N Engl J Med. 2005;352:1293–304.0. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy.
Curr Drug Metab. 2009;10:520–9.
1. Koren G, Sakaguchi S, Klieger C, et al. Toward improved pregnancy
labelling. J Popul Ther Clin Pharmacol. 2010;17:e349–57.
2. Jacobsen T, Sifontis N. Drug interactions and toxicities associated
with the antiviral management of cytomegalovirus infection. Am J
Health Syst Pharm. 2010;67:1417–25.
3. Kushner FG, Hand M, Smith SC Jr., et al. 2009 focused updates:
ACC/AHA guidelines for the management of patients with ST-
elevation myocardial infarction (updating the 2004 guideline and 2007
focused update) and ACC/AHA/SCAI guidelines on percutaneous
coronary intervention (updating the 2005 guideline and 2007 focused
update) a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol. 2009;54:2205–41.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/
non-ST-elevation myocardial infarction: a report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 2002
Guidelines for the Management of Patients With Unstable Angina/
Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol.
2007;50:e1–157.
5. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet
and antithrombin agents in the treatment of non-ST-segment eleva-
tion acute coronary syndromes. JAMA. 2005;294:3108–16.
6. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA
focused update of the guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction (updating the
2007 guideline): a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 2011;57:1920–59.
7. Nutescu EA, Lewis RK, Finley JM, et al. Hospital guidelines for use of
low-molecular-weight heparins. Ann Pharmacother. 2003;37:1072–81.
8. Schneeweiss S, Maclure M, Dormuth CR, et al. A therapeutic
substitution policy for proton pump inhibitors: clinical and economic
consequences. Clin Pharmacol Ther. 2006;79:379–88.
9. Epilepsy Therapy Project. State laws or statutes governing generic
substitution by pharmacists. 2011. Available at: http://professionals.
epilepsy.com/page/statutes_by_pharmacists.html. Accessed February
1, 2010.Key Words: ACCF health policy statement y drugs, generic y
formularies y therapeutic equivalency.APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—ACCF/AHA 2011
HEALTH POLICY STATEMENT ON THERAPEUTIC INTERCHANGE AND SUBSTITUTION
Committee
Member Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
avid R. Holmes, Jr
Chair)
Mayo Clinic—Consultant,
Cardiovascular
Diseases
None None None None None None
effrey A. Becker Children’s National
Medical
Center—Director,
Outpatient Cardiology
None None None None None None
hristopher B.
ranger (Recused
rom voting on
ecommendations)
Duke Clinical Research
Institute—Associate
Professor of Medicine;
Director, Cardiac Care
Unit
● AstraZeneca
● Boehringer Ingelheim*
● Bristol-Myers Squibb
● GlaxoSmithKline
● Hoffman La Roche
● Novartis
● Otsuka
● Sanofi-aventis*
● The Medicines
Company
None None ● Astellas*
● AstraZeneca*
● Boehringer Ingelheim*
● Bristol-Myers Squibb*
● GlaxoSmithKline*
● Medtronic Vascular
● Merck*
● Sanofi-aventis*
● The Medicines
Company*
None None
MR
C
f
r
B
1304 Holmes et al. JACC Vol. 58, No. 12, 2011
Health Policy Statement: Therapeutic Substitution September 13, 2011:1287–307Committee
Member Employment Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
arian C. Limacher University of Florida,
Division of
Cardiovascular
Medicine—Senior
Associate Dean for
Faculty Affairs and
Professional
Development;
Suncoast Endowed
Professor of
Cardiovascular
Research
None None None None None None
obert Lee Page II University of Colorado
School of Pharmacy—
Associate Professor of
Clinical Pharmacy
None None None None None None
athy Sila (Recused
rom voting on
ecommendations)
Case Western Reserve
University School of
Medicine, Neurological
Institute Case Medical
Center—George M.
Humphrey II Professor
of Neurology; Director,
Stroke &
Cerebrovascular
Center
● Axio
● Elekta
● EvaHeart Medical†
● Hoffman La Roche
● Monteris
None None ● AGA Medical† None None
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated
in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the
time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity; or ownership of
$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that
exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
*Significant relationship. †No financial benefit.
APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—ACCF/AHA 2011
HEALTH POLICY STATEMENT ON THERAPEUTIC INTERCHANGE AND SUBSTITUTION
Peer Reviewer Representation Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
iykem Bozkurt Official Reviewer—AHA None None None ● Forest
Pharmaceuticals*
● Amgen
● Corthera
● Novartis
None
Robert A.
Harrington
Official Reviewer—ACCF
Clinical Quality Committee
● APT Nidus Center
● AstraZeneca*
● Baxter
● Bristol-Myers Squibb
● CSL Behring
● Eisai
● Gilead Sciences
● Merck
● Mitsubishi-Tanabe
● Novartis†
● Orexigen
Therapeutics
● Regado
● Sanofi-aventis
● Schering-Plough*
None None ● AstraZeneca
● Baxter
● Bristol-Myers Squibb*
● GlaxoSmithKline*
● Merck*
● Portola*
● Schering-Plough*
● The Medicines Company
None None
Roger Kelley Official Reviewer—AHA None None None None None None
R
K
T
L
J
G
M
1305JACC Vol. 58, No. 12, 2011 Holmes et al.
September 13, 2011:1287–307 Health Policy Statement: Therapeutic SubstitutionPeer Reviewer Representation Consultant
Speaker’s
Bureau
Ownership/
Partnership/
Principal Personal Research
Institutional,
Organizational,
or Other
Financial Benefit
Expert
Witness
ichard J.
ovacs
Official Reviewer—ACCF
Board of Trustees
● Biomedical Systems
● Cook Incorporated-
Medical Institute*
● Eli Lilly*
● Essentialis
● Xenoport
None None None None None
homas J.
ewandowski
Official Reviewer—ACCF
Board of Governors
None ● AstraZeneca None None None None
afna L. Cox Content Reviewer—ACCF
Board of Governors
● AstraZeneca
● Bayer
● Boehringer Ingelheim
● Sanofi-aventis
None None ● Pfizer* None None
Joseph P.
Drozda, Jr.
Content Reviewer—Clinical
Quality Committee
None None None None None None
Harlan M.
Krumholz
Content Reviewer—Clinical
Quality Committee
● Centegen/Life
Technologies*
None None None None None
.B. John
ancini
Content Reviewer—ACCF
Board of Governors
● GlaxoSmithKline
● Merck
● Pfizer
● Sanofi-aventis
None None ● Merck* None None
Frederick A.
Masoudi
Content Reviewer—Clinical
Quality Committee
None None None None None None
John F. Robb Content Reviewer—ACCF
Board of Governors
None None None None None None
Robert N.
Vincent
Content Reviewer—Adult
Congenital/Pediatric
Cardiology Council
None None None None None None
Lawrence Yu Content Reviewer—U.S. Food
and Drug Administration
None None None None None None
This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect
relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the
business entity; or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the
previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose
of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.
*Significant relationship. †No financial benefit.
ACCF indicates American College of Cardiology Foundation; and AHA, American Heart Association.
APPENDIX 3. STATE LAWS OR STATUTES GOVERNING GENERIC SUBSTITUTION BY PHARMACISTS
State
Allows for Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Mandates Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Allows for Brand
If Requested by
Patient
Mandates Brand
Only If Indicated
by Physician
To Ensure Brand Name Only, Physician Must
Indicate the Following on the Written Prescription
OR Communicate Orally
Alabama    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.”
Alaska    In the physician’s handwriting, the words “Brand
Medically Necessary” must appear on the
prescription.
Arizona    Clearly display on the prescription “DAW” or other
wording indicative of Substitution Not Permitted.
Arkansas    In the physician’s handwriting, indicate that the
product ordered should not be substituted.
California    In the physician’s handwriting, the words “Do Not
substitute” must appear on the prescription.
Colorado    In the physician’s handwriting, the words “Dispense
As Written” must appear on the prescription.
Connecticut    In the physician’s handwriting, indicate that the
product ordered should not be substituted.
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Allows for Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Mandates Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Allows for Brand
If Requested by
Patient
Mandates Brand
Only If Indicated
by Physician
To Ensure Brand Name Only, Physician Must
Indicate the Following on the Written Prescription
OR Communicate Orally
Delaware    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.”
Florida    In the physician’s handwriting, the words “Medically
Necessary” must appear on the prescription.
Georgia    In the physician’s handwriting, the words “Brand
Necessary” must appear on the prescription.
Hawaii    In the physician’s handwriting, the words “Brand
Medically Necessary” must appear on the
prescription. Mandates Brand Only for
Anticonvulsant Medications.
Idaho    Physician must indicate “Brand Only” by checking
the “Brand Only” box on the prescription.
Illinois    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense AS Written.”
Indiana    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.”
Iowa    Physician shall communicate to pharmacist that
product should not be substituted.
Kansas    In the physician’s handwriting, the words “Dispense
As Written” must appear on the prescription.
Kentucky    In the physician’s handwriting, the words “Do not
substitute” must appear on the prescription.
Louisiana    Physician must indicate “Brand Only” by checking
the “Dispense as Written or DAW” box on the
prescription.
Maine   In the physician’s handwriting, the words “Dispense
As Written,” “DAW,” “Brand,” or “Brand
Necessary” must appear on the prescription.
Maryland    Physician shall communicate to pharmacist that
product should not be substituted.
Massachusetts   In the physician’s handwriting, the words “No
Substitution” must appear on the prescription.
Michigan    In the physician’s handwriting, the words “Dispense
As Written” or “DAW” must appear on the
prescription.
Minnesota    In the physician’s handwriting, the words “Dispense
As Written” or “DAW” must appear on the
prescription.
Mississippi    Physician shall communicate to pharmacist that
product should not be substituted.
Missouri    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.”
Montana    In the physician’s handwriting, the words “Brand
Medically Necessary” must appear on the
prescription.
Nebraska    In the physician’s handwriting, the words “Dispense
As Written,” “DAW” or similar statements must
appear on the prescription.
Nevada    In the physician’s handwriting, the words “Dispense
As Written” must appear on the prescription.
New Hampshire    Physician must specify that the Brand is Medically
Necessary.
New Jersey    Physician must initial next to the option “Do Not
Substitute” on the prescription.
New Mexico    In the physician’s handwriting, the words “No
Substitution” or “No Sub” must appear on the
prescription.
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Allows for Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Mandates Generic
Substitution by
Pharmacists If
“Brand Only” Not
Indicated by
Physician
Allows for Brand
If Requested by
Patient
Mandates Brand
Only If Indicated
by Physician
To Ensure Brand Name Only, Physician Must
Indicate the Following on the Written Prescription
OR Communicate Orally
New York   In the physician’s handwriting, “DAW” must appear
on the prescription.
North Carolina    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.” Narrow
Therapeutic Range Drugs must be dispensed as
originally prescribed.
North Dakota    In the physician’s handwriting, the words “Brand
Necessary” must appear on the prescription.
Ohio    In the physician’s handwriting, the words “Dispense
As Written” or “DAW” must appear on the
prescription.
Oklahoma    Physician shall communicate to pharmacist that
product should not be substituted.
Oregon    In the physician’s handwriting, the words “No
Substitution” or “N.S” must appear on the
prescription.
Pennsylvania    Physician shall communicate to pharmacist that
product should not be substituted.
Rhode Island    In the physician’s handwriting, the words “Dispense
As Brand Name Necessary” must appear on the
prescription.
South Carolina    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense as Written.”
South Dakota    In the physician’s handwriting, the words “Brand
Necessary” must appear on the prescription.
Tennessee    In the physician’s handwriting, the words “Dispense
As Written,” “DAW,” or other language of intent
must appear on the prescription.
Texas    In the physician’s handwriting, the words “Brand
Necessary” or “Brand Medically Necessary” must
appear on the prescription.
Utah    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written” OR in the
physician’s handwriting, the words “Dispense as
Written” must appear on the prescription.
Vermont    In the physician’s handwriting, the words “Brand
Necessary” or “No substitution” must appear on
the prescription.
Virginia    In the physician’s handwriting, the words “Brand
Necessary” must appear on the prescription.
Washington    Sign the prescription signature line labeled “May Not
Substitute” or “Dispense As Written.”
West Virginia    In the physician’s handwriting, the words “Brand
Medically Necessary” must appear on the
prescription.
Wisconsin    In the physician’s handwriting, the words “No
Substitutions” or “N.S.” must appear on the
prescription.
Wyoming    In the physician’s handwriting, the words “Brand
Medically Necessary” must appear on the
prescription.
The information presented in this chart is for reference only. Prescribers, please consult the appropriate authorities in your state for specific requirements and wording to be sure that medications are
dispensed as you have determined appropriate for your patient. Any questions should be directed to those authorities. Reprinted with permission from Epilepsy Therapy Project (99). ©2003–2011
Epilepsy.com. All rights reserved. This information was reviewed and verified as current in February 2010.
